Annovis to Present Buntanetap's Alzheimer's Research at CTAD 2024

Annovis Bio Inc., a late-stage clinical drug platform company, is set to participate in the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled from October 29 to November 1, 2024, in Madrid, Spain. The company, which focuses on developing groundbreaking treatments for neurodegenerative conditions such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), will present two scientific posters at the event.

Dr. Maria Maccecchini, the President and CEO of Annovis Bio, will share insights through these posters. The first poster, LP023, titled "Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients," will be presented from October 29 to October 30, 3:00 PM – 5:00 PM (CET). The second poster, LP074, titled "Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer’s Clinical Studies," will be displayed on October 31, 7:15 AM – 5:00 PM (CET).

Post-conference, these posters will be accessible on the Annovis Bio website for further reference. The CTAD 2024 conference is a significant event that gathers leading figures from the Alzheimer’s research arena, including representatives from pharmaceutical firms, academic research institutions, and patient advocacy organizations. It serves as a vital platform for discussing new and innovative treatment strategies for Alzheimer’s disease.

Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is committed to tackling neurodegenerative diseases like AD and PD. The company employs a novel approach that targets multiple neurotoxic proteins, aiming to restore brain function and enhance the quality of life for patients afflicted with these conditions.

For those interested in keeping abreast of Annovis Bio’s developments, the company offers an email alert system for press releases and industry updates. Interested parties are encouraged to register for these alerts to stay informed about the latest news and updates. Additionally, the company’s investor website has been updated to provide comprehensive access to news, financial reports, and other significant information.

Annovis Bio continues to make strides in its research and clinical trials, striving to find effective treatments for debilitating neurodegenerative diseases. The presentations at the CTAD 2024 conference highlight the company’s ongoing commitment to innovation and its dedication to improving patient outcomes through scientific advancements.